REGN241101C1015000
- 1.80
- -1.50-45.45%
Regeneron Pharmaceuticals Newsroom
EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss
Market Climbs as Investors Prepare for Biggest Earnings Week of the Year | Live Stock
Bernstein Adjusts Price Target on Regeneron Pharmaceuticals to $1,135 From $1,210, Maintains Outperform Rating
Barclays Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,080
Possible Bearish Signals With Regeneron Pharmaceuticals Insiders Disposing Stock
Earnings Preview: REGN to Report Financial Results Pre-market on October 31
Weekly Buzz: Is Tesla a sign of earnings to come?
Friday Market Falls With Busy Business Ahead | Wall Street Today
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
Regeneron Pharmaceuticals Analyst Ratings
Mooer's Stories | How Stock_Drift Navigates Irrational Markets
Friday Market Climbs After Big Earnings, and More to Come | Live Moovin' Stocks
Lilly's Ebglyss Shown to Be Effective in Former Dupixent Users
RBC Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,260
Sanofi Posts Q3 Revenue Beat as Dupixent Sales Jump
Evercore Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,175
$100 Invested In This Stock 15 Years Ago Would Be Worth $5,800 Today
Regeneron, Sanofi Report Dupixent 'Significantly' Reduced Itch, Hive Activity in Phase 3 Study for CSU
Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,250
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $1,080 to $1,242